| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/02/2003 | EP1267938A1 Proteins for use as carriers in conjugate vaccines |
| 01/02/2003 | EP1267934A2 A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer |
| 01/02/2003 | EP1267930A1 Cross-reactive displacing antibodies from collagen-binding proteins and method of identification and use |
| 01/02/2003 | EP1267929A2 Farnesyl protein transferase inhibitor combinations with an her2 antibody |
| 01/02/2003 | EP1267928A2 Methods for immunostimulation using bispecific binding agents for the fc receptor of immunoglobulin a and for cancer cells or infectious antigen |
| 01/02/2003 | EP1267927A1 Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2 |
| 01/02/2003 | EP1267926A2 Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2 |
| 01/02/2003 | EP1267925A1 Treatment of fungal infection with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies |
| 01/02/2003 | EP1267924A2 Immunotherapeutic methods and compositions |
| 01/02/2003 | EP1267923A1 Use of aliphatic quaternary ammonium as adjuvant in a pharmaceutical composition administered by mucosal delivery |
| 01/02/2003 | EP1267922A1 Pneumococcus polysaccharide conjugates for use as vaccine against tetanus and diphtheria |
| 01/02/2003 | EP1267921A1 Composition and method for the prevention and/or the treatment of allergy |
| 01/02/2003 | EP1267920A2 Cold-adapted equine influenza viruses |
| 01/02/2003 | EP1267919A2 A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins |
| 01/02/2003 | EP1267918A1 Method of treatment using ligand-immunogen conjugates |
| 01/02/2003 | EP1267917A1 Angiogenic onchocerca volvulus proteins and uses thereof |
| 01/02/2003 | EP1267909A1 Methods of blocking tissue destruction by autoreactive t cells |
| 01/02/2003 | EP1267908A1 Vaccine for the treatment of atherosclerosis |
| 01/02/2003 | EP1267907A1 Use of mia in immunotherapy |
| 01/02/2003 | EP1267905A2 Composition for the treatment of heart failure |
| 01/02/2003 | EP1267903A1 Methods for treating glaucoma |
| 01/02/2003 | EP1267899A2 Salmonella vaccine materials and methods |
| 01/02/2003 | EP1267898A2 Bile acid containing prodrugs with enhanced bioavailability |
| 01/02/2003 | EP1267893A2 Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections |
| 01/02/2003 | EP1267860A1 Butylnitrone containing compositions for inhibition of cancer development |
| 01/02/2003 | EP1267839A2 Microspheres for active embolization |
| 01/02/2003 | EP1267838A1 Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix |
| 01/02/2003 | EP1267800A1 Methods of modulating hair growth |
| 01/02/2003 | EP1267626A1 Recombinant parainfluenza virus expression systems and vaccines |
| 01/02/2003 | EP1267618A1 Methods for increasing a cytotoxic t lymphocyte response in vivo |
| 01/02/2003 | EP1267616A1 Methods of modulating hair growth |
| 01/02/2003 | EP0999853B1 Stabilized antibody formulation |
| 01/02/2003 | EP0979284B1 Reagents for vaccination which generate a cd8 t cell immune response |
| 01/02/2003 | EP0885244B1 Peptide immunogens for vaccination against and treatment of allergy |
| 01/02/2003 | EP0771216B9 Methods and compositions for the specific coagulation of tumoral vasculature |
| 01/02/2003 | EP0723440B1 Therapeutic delivery compositions and methods of use thereof |
| 01/01/2003 | CN1388136A Double-specificity antibody resisting human ovary cancer and human CD3 |
| 01/01/2003 | CN1387914A Hepatitis B vaccine with lactic acid-ethanediol copolymer as adjuvant |
| 01/01/2003 | CN1097468C Products containing G-CSF and TNF binding protein |
| 01/01/2003 | CN1097467C Vaccine compositions |
| 01/01/2003 | CN1097466C Living salmonella vaccine |
| 12/31/2002 | US6500941 Secreted by human breast cancer mda-mb-175 cells, leads to the formation of a constitutive active receptor complex and stimulates these cells in an autocrine manner |
| 12/31/2002 | US6500933 Methods of preparing carbohydrate crosslinked glycoprotein crystals |
| 12/31/2002 | US6500924 Package for using antagonists of the vitronectin receptor alpha-v beta3 comprising a metalloproteinase polypeptide of given amino acid sequence; treating arthritis, rheumatoid arthritis, retinopathy and tumors |
| 12/31/2002 | US6500923 Isolated polypeptide that binds to an autoantibody from a dermatomyositis patient to provide means by which dermatomyositis can be detected by way of differential diagnosis |
| 12/31/2002 | US6500919 Melanoma associated antigenic polypeptide, epitopes thereof and vaccines against melanoma |
| 12/31/2002 | US6500869 Sun-protection formulations active against herpes simplex viruses |
| 12/31/2002 | US6500800 Composition and method for causing photodynamic damage to target cells |
| 12/31/2002 | US6500672 A competitive assay for binding activity to recombinant hepatocyte nuclear factor-4 receptors, a chimeric receptor comprising the ligand binding domain of a hnf-4 receptor and dna binding domain of another receptor |
| 12/31/2002 | US6500663 Unique associated Kaposi's sarcoma virus sequences and uses thereof |
| 12/31/2002 | US6500662 Infectious cdna clones of positive polarity rna viruses and the construction of vaccines, in particular, swine vaccines, using such cdna clones |
| 12/31/2002 | US6500654 Cardiac-related ankyrin-repeat protein kinase |
| 12/31/2002 | US6500653 Nucleic acids and polypeptides which resemble RHO and which interact with cell signaling pathways and proteins |
| 12/31/2002 | US6500641 Expression vector wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen protein or peptide, a polynucleotide encoding a cell binding element, |
| 12/31/2002 | US6500638 Nucleotide sequences for use in the diagnosis and treatment of prostate cancer |
| 12/31/2002 | US6500623 Pseudotyped with vesicular stomatitis virus g protein; modifying portion of the pol gene of dna molecule that includes a complete retroviral genome such that it cannot produce a protease and reverse transcriptase |
| 12/31/2002 | US6500613 Isolated pneumococcal surface protein c, pspc, of strepto-coccus pneumoniae having alpha-helical, proline rich and repeat regions |
| 12/31/2002 | US6500453 Drug delivery |
| 12/31/2002 | US6500438 In ovo vaccination against coccidiosis |
| 12/31/2002 | US6500437 Fusion protein comprising specified amino acid sequence |
| 12/31/2002 | US6500435 Vaccine comprising at least three isolated actinobacillus pleuropneumoniae cytolysin proteins having specified amino acid sequences |
| 12/31/2002 | US6500434 Protecting against a bacterial infection caused by pilus-bearing bacteria in a human being using vaccine of complexes of bacterial pili proteins |
| 12/31/2002 | US6500433 Polypeptide fragments capable of competition with Streptococcus mutans antigen I/II |
| 12/31/2002 | US6500432 Method to enhance an immune response of nucleic acid vaccination |
| 12/31/2002 | US6500419 Method for introducing and expressing RNA in animal cells |
| 12/31/2002 | CA2157867C High molecular weight surface proteins of non-typeable haemophilus |
| 12/28/2002 | CA2391205A1 Benzoic acid substituted benzopyrans for the treatment of atherosclerosis |
| 12/27/2002 | WO2002103362A2 Cancer associated protein |
| 12/27/2002 | WO2002103029A2 Methods for sterilizing preparations of monoclonal immunoglobulins |
| 12/27/2002 | WO2002103004A1 Surface modification for improving biocompatibility |
| 12/27/2002 | WO2002103002A2 Gene associated with leishmania parasite virulence |
| 12/27/2002 | WO2002102999A1 Attenuated circovirus |
| 12/27/2002 | WO2002102990A2 Fibroblast growth factor and nucleic acid encoding same |
| 12/27/2002 | WO2002102987A2 Methods and compositions based on protein interactions with mastermind |
| 12/27/2002 | WO2002102975A2 Dna molecules and recombinant dna molecules for producing humanized monoclonal antibodies to s. mutans |
| 12/27/2002 | WO2002102973A2 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| 12/27/2002 | WO2002102972A2 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| 12/27/2002 | WO2002102971A2 Methods of utilizing cultured hematopoietic progenitor cells for inducing immunological tolerance |
| 12/27/2002 | WO2002102855A2 In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| 12/27/2002 | WO2002102854A2 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| 12/27/2002 | WO2002102853A2 Cd4-specific antibody trx1 and uses therefor |
| 12/27/2002 | WO2002102836A2 Moraxella (branhamella) catarrhalis antigens |
| 12/27/2002 | WO2002102829A2 Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus |
| 12/27/2002 | WO2002102828A2 Chimeric flavivirus vectors |
| 12/27/2002 | WO2002102411A2 Method for treating psoriasis by using an il-17d antagonist |
| 12/27/2002 | WO2002102410A1 Subunit vaccines and processes for the production thereof |
| 12/27/2002 | WO2002102409A1 Inactivated mycobacterial ompatb and uses thereof |
| 12/27/2002 | WO2002102408A1 Moraxella bovis cytotoxin, cytotoxin gene, antibodies and vaccines for prevention and treatment of moraxella bovis infections |
| 12/27/2002 | WO2002102407A1 Therapeutical vaccination |
| 12/27/2002 | WO2002102404A1 Uses of cytokines |
| 12/27/2002 | WO2002102402A1 Anticancer agents |
| 12/27/2002 | WO2002102324A2 Anti-arthropod vector vaccines methods of selecting and uses thereof |
| 12/27/2002 | WO2002102320A2 Fce fusion proteins for treatment of allergy and asthma |
| 12/27/2002 | WO2002102312A2 Combination therapy of gamma-interferon and b cell specific antibodies |
| 12/27/2002 | WO2002102310A2 Proteins associated with cell growth, differentiation, and death |
| 12/27/2002 | WO2002102307A2 Nucleoside vaccine adjuvants |
| 12/27/2002 | WO2002102306A2 Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy |
| 12/27/2002 | WO2002102305A2 Adjuvant composition for mucosal and injection delivered vaccines |
| 12/27/2002 | WO2002102299A2 Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
| 12/27/2002 | WO2002102229A2 Diagnosing tumorigenicity and determining resistance to anticancer therapy |